Cell:高福与颜宁教授揭示胆固醇转运和埃博拉病毒入侵关键机制

2016-05-28 MedSci MedSci原创

2016年5月26日,国际著名生物学权威杂志《Cell》在线发表微生物研究所高福院士团队和清华大学颜宁课题组的合作文章Structural  Insights into the Niemann-Pick C1 (NPC1)-Mediated Cholesterol Transfer and Ebola Infection,首次报导了人类胆固醇转运体NPC1,以及NPC1与埃博拉病毒表

2016年5月26日,国际著名生物学权威杂志Cell在线发表微生物研究所高福院士团队和清华大学颜宁课题组的合作报导了人类胆固醇转运体NPC1,以及NPC1与埃博拉病毒表面融合蛋白复合物的冷冻电镜结构,为深入理解NPC1介导的胆固醇转运和埃博拉病毒入侵提供了重要线索。


今年1月份,高福院士有关埃博拉病毒入侵也有研究成果发表在Cell上(Cell:高福院士揭示埃博拉病毒入侵的新机制)。颜宁团队在结构生物学领域有一系列重大突破。



NPC1
(左)及NPC1与埃博拉GPcl的复合物(右)结构图

NPC1是位于内吞体(endosome)和溶酶体(lysosome)上的一个多次跨膜蛋白,由1278个氨基酸残基组成,包含13次跨膜螺旋,具有三个大的腔内结构域(A, C和I)。NPC1在体内主要负责胆固醇转运,其氨基酸突变可能会导致Niemann-Pick C综合症,表现为儿童神经发育迟缓,认知障碍或失聪,严重时会导致儿童夭折。 

前人的研究表明,NPC1也是埃博拉病毒进入人体的”大门”。在具有埃博拉抗性的细胞中表达NPC1会介导埃博拉病毒的感染;反之,其缺失突变会使对埃博拉病毒敏感的细胞产生抗性。这一特征也使得NPC1成为埃博拉病毒防治中最热门的药物靶点之一。在2016年1月15日,高福院士团队在Cell杂志在线发表了Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1《埃博拉病毒糖蛋白结合内吞体受体NPC1的分子机制》,该文章报导了埃博拉病毒的表面融合蛋白GPcl与NPC1结构域C的晶体结构,发现结构域C主要利用两个突出来的环状结构插入激活态糖蛋白头部的疏水凹槽里,从而发生相互作用。然而,由于缺乏NPC1全长膜蛋白的结构信息,其它两个腔内结构域A和I在埃博拉入侵中的作用并不清楚。 

在最新的文章中,颜宁课题组和高福院士课题组合作,利用单颗粒冷冻电镜技术重构了4.4 Å分辨率的NPC1全长膜蛋白结构,以及6.6 Å分辨率的NPC1与埃博拉GPcl复合物的电镜结构。结构显示NPC1在去垢剂溶液中以单体形式存在,高度约为140 Å,其2-13次跨膜螺旋的结构与已解析的RND家族其它成员的结构较为类似,N端和C端结构域形成一个假二次对称结构;三个腔内结构域中,结构域A像“头”一样坐落在以结构域C和结构域I形成的两个肩膀中间,三个结构域之间形成充分的相互作用。NPC1的结构和大量的生化分析解释了很多与Niemann-Pick C综合症相关的突变。在NPC1与埃博拉GPcl的复合物结构中,一个GPcl三体结合了一个NPC1分子,其结合位点位于结构域C上,靠近结构域A,远离结构域I。结合SPR实验数据,证实了在类似于体内溶酶体的低pH条件下,埃博拉GP蛋白与NPC1有较高的亲和力,其中结构域C的亲和力与GPcl最强,而结构域A与GPcl的亲和力很弱。NPC1与GP的复合物结构进一步揭示了结构域C在介导埃博拉病毒入侵中其主导作用,而结构域A和结构域I起到支撑作用。 

原始出处:

Xin Gong7, Hongwu Qian7, Xinhui Zhou7, Jianping Wu7, Tao Wan7, Pingping Cao, Weiyun Huang, Xin Zhao, Xudong Wang, Peiyi Wang, Yi Shi, George F. Gao, Qiang Zhou, Nieng Yan. Structural Insights into the Niemann-Pick C1 (NPC1)-Mediated Cholesterol Transfer and Ebola Infection. DOI: http://dx.doi.org/10.1016/j.cell.2016.05.022

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799582, encodeId=a0071e9958271, content=<a href='/topic/show?id=baabe0901b6' target=_blank style='color:#2F92EE;'>#病毒入侵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70901, encryptionId=baabe0901b6, topicName=病毒入侵)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Sep 28 20:42:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696264, encodeId=289a169626483, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Mon Dec 26 04:42:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869396, encodeId=1365186939620, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Apr 15 11:42:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650358, encodeId=e0a7165035847, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Jul 07 21:42:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157630, encodeId=cfaa15e63049, content=大的团队尚且合作共事,小团队再单打独斗,迟早出局。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Wed Nov 23 14:33:24 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959653, encodeId=c233195965362, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Oct 10 08:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296463, encodeId=96b1129646316, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377285, encodeId=350a13e7285b0, content=<a href='/topic/show?id=6bc3100e3948' target=_blank style='color:#2F92EE;'>#颜宁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100739, encryptionId=6bc3100e3948, topicName=颜宁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87356, encodeId=20cf8e356b6, content=牛人组合!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat May 28 10:58:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799582, encodeId=a0071e9958271, content=<a href='/topic/show?id=baabe0901b6' target=_blank style='color:#2F92EE;'>#病毒入侵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70901, encryptionId=baabe0901b6, topicName=病毒入侵)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Sep 28 20:42:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696264, encodeId=289a169626483, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Mon Dec 26 04:42:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869396, encodeId=1365186939620, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Apr 15 11:42:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650358, encodeId=e0a7165035847, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Jul 07 21:42:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157630, encodeId=cfaa15e63049, content=大的团队尚且合作共事,小团队再单打独斗,迟早出局。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Wed Nov 23 14:33:24 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959653, encodeId=c233195965362, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Oct 10 08:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296463, encodeId=96b1129646316, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377285, encodeId=350a13e7285b0, content=<a href='/topic/show?id=6bc3100e3948' target=_blank style='color:#2F92EE;'>#颜宁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100739, encryptionId=6bc3100e3948, topicName=颜宁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87356, encodeId=20cf8e356b6, content=牛人组合!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat May 28 10:58:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-12-26 yzh409
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799582, encodeId=a0071e9958271, content=<a href='/topic/show?id=baabe0901b6' target=_blank style='color:#2F92EE;'>#病毒入侵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70901, encryptionId=baabe0901b6, topicName=病毒入侵)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Sep 28 20:42:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696264, encodeId=289a169626483, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Mon Dec 26 04:42:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869396, encodeId=1365186939620, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Apr 15 11:42:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650358, encodeId=e0a7165035847, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Jul 07 21:42:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157630, encodeId=cfaa15e63049, content=大的团队尚且合作共事,小团队再单打独斗,迟早出局。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Wed Nov 23 14:33:24 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959653, encodeId=c233195965362, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Oct 10 08:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296463, encodeId=96b1129646316, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377285, encodeId=350a13e7285b0, content=<a href='/topic/show?id=6bc3100e3948' target=_blank style='color:#2F92EE;'>#颜宁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100739, encryptionId=6bc3100e3948, topicName=颜宁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87356, encodeId=20cf8e356b6, content=牛人组合!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat May 28 10:58:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1799582, encodeId=a0071e9958271, content=<a href='/topic/show?id=baabe0901b6' target=_blank style='color:#2F92EE;'>#病毒入侵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70901, encryptionId=baabe0901b6, topicName=病毒入侵)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Sep 28 20:42:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696264, encodeId=289a169626483, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Mon Dec 26 04:42:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869396, encodeId=1365186939620, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Apr 15 11:42:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650358, encodeId=e0a7165035847, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Jul 07 21:42:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157630, encodeId=cfaa15e63049, content=大的团队尚且合作共事,小团队再单打独斗,迟早出局。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Wed Nov 23 14:33:24 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959653, encodeId=c233195965362, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Oct 10 08:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296463, encodeId=96b1129646316, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377285, encodeId=350a13e7285b0, content=<a href='/topic/show?id=6bc3100e3948' target=_blank style='color:#2F92EE;'>#颜宁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100739, encryptionId=6bc3100e3948, topicName=颜宁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87356, encodeId=20cf8e356b6, content=牛人组合!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat May 28 10:58:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1799582, encodeId=a0071e9958271, content=<a href='/topic/show?id=baabe0901b6' target=_blank style='color:#2F92EE;'>#病毒入侵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70901, encryptionId=baabe0901b6, topicName=病毒入侵)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Sep 28 20:42:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696264, encodeId=289a169626483, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Mon Dec 26 04:42:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869396, encodeId=1365186939620, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Apr 15 11:42:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650358, encodeId=e0a7165035847, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Jul 07 21:42:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157630, encodeId=cfaa15e63049, content=大的团队尚且合作共事,小团队再单打独斗,迟早出局。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Wed Nov 23 14:33:24 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959653, encodeId=c233195965362, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Oct 10 08:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296463, encodeId=96b1129646316, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377285, encodeId=350a13e7285b0, content=<a href='/topic/show?id=6bc3100e3948' target=_blank style='color:#2F92EE;'>#颜宁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100739, encryptionId=6bc3100e3948, topicName=颜宁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87356, encodeId=20cf8e356b6, content=牛人组合!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat May 28 10:58:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-11-23 studylzc

    大的团队尚且合作共事,小团队再单打独斗,迟早出局。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1799582, encodeId=a0071e9958271, content=<a href='/topic/show?id=baabe0901b6' target=_blank style='color:#2F92EE;'>#病毒入侵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70901, encryptionId=baabe0901b6, topicName=病毒入侵)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Sep 28 20:42:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696264, encodeId=289a169626483, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Mon Dec 26 04:42:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869396, encodeId=1365186939620, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Apr 15 11:42:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650358, encodeId=e0a7165035847, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Jul 07 21:42:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157630, encodeId=cfaa15e63049, content=大的团队尚且合作共事,小团队再单打独斗,迟早出局。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Wed Nov 23 14:33:24 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959653, encodeId=c233195965362, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Oct 10 08:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296463, encodeId=96b1129646316, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377285, encodeId=350a13e7285b0, content=<a href='/topic/show?id=6bc3100e3948' target=_blank style='color:#2F92EE;'>#颜宁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100739, encryptionId=6bc3100e3948, topicName=颜宁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87356, encodeId=20cf8e356b6, content=牛人组合!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat May 28 10:58:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-10-10 维他命
  7. [GetPortalCommentsPageByObjectIdResponse(id=1799582, encodeId=a0071e9958271, content=<a href='/topic/show?id=baabe0901b6' target=_blank style='color:#2F92EE;'>#病毒入侵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70901, encryptionId=baabe0901b6, topicName=病毒入侵)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Sep 28 20:42:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696264, encodeId=289a169626483, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Mon Dec 26 04:42:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869396, encodeId=1365186939620, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Apr 15 11:42:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650358, encodeId=e0a7165035847, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Jul 07 21:42:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157630, encodeId=cfaa15e63049, content=大的团队尚且合作共事,小团队再单打独斗,迟早出局。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Wed Nov 23 14:33:24 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959653, encodeId=c233195965362, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Oct 10 08:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296463, encodeId=96b1129646316, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377285, encodeId=350a13e7285b0, content=<a href='/topic/show?id=6bc3100e3948' target=_blank style='color:#2F92EE;'>#颜宁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100739, encryptionId=6bc3100e3948, topicName=颜宁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87356, encodeId=20cf8e356b6, content=牛人组合!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat May 28 10:58:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1799582, encodeId=a0071e9958271, content=<a href='/topic/show?id=baabe0901b6' target=_blank style='color:#2F92EE;'>#病毒入侵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70901, encryptionId=baabe0901b6, topicName=病毒入侵)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Sep 28 20:42:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696264, encodeId=289a169626483, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Mon Dec 26 04:42:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869396, encodeId=1365186939620, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Apr 15 11:42:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650358, encodeId=e0a7165035847, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Jul 07 21:42:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157630, encodeId=cfaa15e63049, content=大的团队尚且合作共事,小团队再单打独斗,迟早出局。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Wed Nov 23 14:33:24 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959653, encodeId=c233195965362, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Oct 10 08:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296463, encodeId=96b1129646316, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377285, encodeId=350a13e7285b0, content=<a href='/topic/show?id=6bc3100e3948' target=_blank style='color:#2F92EE;'>#颜宁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100739, encryptionId=6bc3100e3948, topicName=颜宁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87356, encodeId=20cf8e356b6, content=牛人组合!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat May 28 10:58:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-05-30 syscxl
  9. [GetPortalCommentsPageByObjectIdResponse(id=1799582, encodeId=a0071e9958271, content=<a href='/topic/show?id=baabe0901b6' target=_blank style='color:#2F92EE;'>#病毒入侵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70901, encryptionId=baabe0901b6, topicName=病毒入侵)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Sep 28 20:42:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696264, encodeId=289a169626483, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Mon Dec 26 04:42:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869396, encodeId=1365186939620, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Apr 15 11:42:00 CST 2017, time=2017-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650358, encodeId=e0a7165035847, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Thu Jul 07 21:42:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157630, encodeId=cfaa15e63049, content=大的团队尚且合作共事,小团队再单打独斗,迟早出局。, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Wed Nov 23 14:33:24 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959653, encodeId=c233195965362, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Oct 10 08:42:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296463, encodeId=96b1129646316, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377285, encodeId=350a13e7285b0, content=<a href='/topic/show?id=6bc3100e3948' target=_blank style='color:#2F92EE;'>#颜宁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100739, encryptionId=6bc3100e3948, topicName=颜宁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b27406, createdName=syscxl, createdTime=Mon May 30 00:42:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87356, encodeId=20cf8e356b6, content=牛人组合!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Sat May 28 10:58:00 CST 2016, time=2016-05-28, status=1, ipAttribution=)]
    2016-05-28 medcardio

    牛人组合!

    0

相关资讯

WHO:埃博拉疫情已结束

位于瑞士日内瓦的世界卫生组织(WHO)总干事陈冯富珍日前宣布,埃博拉疫情不再是“构成国际关注的突发公共卫生事件”。她是在听取了由WHO召集以讨论埃博拉疫情的突发事件委员会给出的建议后作出这一声明的。“正如专家们在会面期间所指出的,西非的埃博拉应对能力已经很强大。”陈冯富珍表示,“在应对埃博拉上,这3个国家如今已拥有全世界最大的专家库。”

分离出三株抗埃博拉病毒单克隆抗体

中国科学家领衔的团队16日在英国《科学报告》杂志发表论文说,他们成功分离出三株具有高中和能力的抗埃博拉病毒单克隆抗体,这些抗体有潜力作为候选药物用于预防和治疗埃博拉病毒感染。

NEJM:ChAd3疫苗一期研究结果

2014年西非埃博拉病毒爆发达到高峰,导致超过11,000例死亡,开发有效的埃博拉疫苗是控制事件未来爆发的有效措施。在这项1期研究中,研究者对来自英国牛津的60名健康志愿者接种单剂量的以表达埃博拉病毒扎伊尔株(ZEBOV)糖蛋白的黑猩猩腺病毒3(ChAd3)疫苗。疫苗分为3个不同剂量(病毒颗粒):1×1010、2.5×1010和5×1010。不同剂量组分别有20名参与者。研究期间没有发现不同剂量疫

BMJ:塞拉利昂埃博拉病幸存者调查研究

研究者在塞拉利昂西部地区进行了一项回顾性队列研究,评估埃博拉病毒感染患者从治疗中心出院后,再次复发致死性感染的发生率,探究感染剂量对病死率的影响。 该研究纳入了151名从克里镇治疗中心治疗出院的埃博拉病毒感染患者,在出院后4-9个月随访幸存者的生命体征等情况,在出院后6-13个月,再次进行检查。对4名出院后死亡的幸存者进行了口头尸检。对仍生活在西部地区的幸存者进行了采访,包括他们的家庭成员。

华人学者为HIV、埃博拉治疗照亮前路

最近,由利兹大学领导的一个华人研究小组首次观察到了“艾滋病病毒(HIV)和埃博拉病毒如何附着于细胞以传播感染”。这项研究结果,发表在今天出版的《Angewandte Chemie》,为这类病毒的治疗提供了一种新的方法:不是破坏病原体,而是阻断它们如何与细胞相互作用。 本文首席作者、来自利兹大学Astbury结构分子生物学中心的郭媛(Yuan Guo)博士说:“直到现在,这些病毒是如何附着到细胞上

NEJM:埃博拉疫苗rVSV-ZEBOV一期试验结果

以表达埃博拉病毒扎伊尔株(ZEBOV)糖蛋白的可复制重组水泡性口炎病毒(rVSV)候选疫苗为对象,开展了快速的安全性和免疫原性试验。该随机、双盲、对照1期试验中,研究者对158名健康的欧洲和非洲成年人接种了不同剂量的rVSV-ZEBOV疫苗,剂量为30万-5000万个噬菌斑形成单位(PFU)或安慰剂,以评估该疫苗的安全性、副作用和免疫原性。研究期间没有疫苗相关严重不良事件的报告。轻中度早发型反应原